Grail Inc
NASDAQ:GRAL

Watchlist Manager
Grail Inc Logo
Grail Inc
NASDAQ:GRAL
Watchlist
Price: 18.35 USD 7.06% Market Closed
Market Cap: 616.6m USD
Have any thoughts about
Grail Inc?
Write Note

Grail Inc
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Grail Inc
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
Grail Inc
NASDAQ:GRAL
Intangible Assets
$2.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Intangible Assets
$66.6B
CAGR 3-Years
-5%
CAGR 5-Years
28%
CAGR 10-Years
46%
Gilead Sciences Inc
NASDAQ:GILD
Intangible Assets
$20.5B
CAGR 3-Years
-15%
CAGR 5-Years
7%
CAGR 10-Years
6%
Amgen Inc
NASDAQ:AMGN
Intangible Assets
$28.9B
CAGR 3-Years
25%
CAGR 5-Years
34%
CAGR 10-Years
8%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Intangible Assets
$831.6m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Intangible Assets
$1.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Grail Inc
Glance View

Market Cap
609.3m USD
Industry
Biotechnology

Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

GRAL Intrinsic Value
19.1 USD
Undervaluation 4%
Intrinsic Value
Price

See Also

What is Grail Inc's Intangible Assets?
Intangible Assets
2.7B USD

Based on the financial report for Dec 31, 2023, Grail Inc's Intangible Assets amounts to 2.7B USD.

What is Grail Inc's Intangible Assets growth rate?
Intangible Assets CAGR 1Y
-8%

Over the last year, the Intangible Assets growth was -8%.

Back to Top